– Reuters Citing A NASA Official
To Avoid Supply Crunch, FDA Temporarily Allows Higher Impurity Levels In Merck’s Diabetes Drug: Report
The FDA recently became aware of a nitrosamine impurity, Nitroso-STG-19 or NTTP, in certain samples of Merck & Co Inc's (NYSE: MRK) type 2 diabetes drug Januvia/Janumet (sitagliptin).
